Literature DB >> 30107024

The financial contribution of the multiple sclerosis specialist.

Joseph R Berger1.   

Abstract

PURPOSE OF REVIEW: To examine the financial effect of the multiple sclerosis (MS) specialist on the academic health center (AHC). RECENT
FINDINGS: Using data derived from an academic MS center with respect to patient numbers and practice pattern regarding diagnostic studies and disease-modifying therapies (DMT) coupled with reasonable assumptions regarding the profit margin for tests and treatments, 1 full-time MS specialist (1 clinical full-time equivalent [cFTE]) may annually generate downstream revenue exceeding $8,000,000. If all diagnostic studies and therapies were obtained at the facility, the potential revenue generated for the facility can exceed $25,000,000 per 1 cFTE. These calculations do not include the professional net revenue generated by referrals to other professionals.
SUMMARY: With current models of reimbursement for health care, the MS specialist provides an enormous potential source of revenue for the AHC. This information is critically important in obtaining institutional support for the provision of labor-intensive MS care.

Entities:  

Year:  2017        PMID: 30107024      PMCID: PMC6081969          DOI: 10.1212/CPJ.0000000000000360

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  10 in total

1.  Relative value units: from A to Z (Part I of IV).

Authors:  Kathryn P Glass; Jeffery R Anderson
Journal:  J Med Pract Manage       Date:  2002 Mar-Apr

2.  Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study.

Authors:  M H Barnett; D B Williams; S Day; P Macaskill; J G McLeod
Journal:  J Neurol Sci       Date:  2003-09-15       Impact factor: 3.181

3.  Using a productivity-based physician compensation program at an academic health center: a case study.

Authors:  Margie C Andreae; Gary L Freed
Journal:  Acad Med       Date:  2002-09       Impact factor: 6.893

4.  An AUPN/ANA survey of department leader opinions on the health of US academic neurology.

Authors:  Matthew Rizzo; William C Mobley
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

5.  Use of physicians' services under Medicare's resource-based payments.

Authors:  Stephanie Maxwell; Stephen Zuckerman; Robert A Berenson
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Medicare payments to the neurology workforce in 2012.

Authors:  Lesli E Skolarus; James F Burke; Brian C Callaghan; Amanda Becker; Kevin A Kerber
Journal:  Neurology       Date:  2015-04-01       Impact factor: 9.910

7.  Burnout and satisfaction with work-life balance among US physicians relative to the general US population.

Authors:  Tait D Shanafelt; Sonja Boone; Litjen Tan; Lotte N Dyrbye; Wayne Sotile; Daniel Satele; Colin P West; Jeff Sloan; Michael R Oreskovich
Journal:  Arch Intern Med       Date:  2012-10-08

8.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

9.  High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).

Authors:  Elaine Kingwell; Feng Zhu; Ruth Ann Marrie; John D Fisk; Christina Wolfson; Sharon Warren; Joanne Profetto-McGrath; Lawrence W Svenson; Nathalie Jette; Virender Bhan; B Nancy Yu; Lawrence Elliott; Helen Tremlett
Journal:  J Neurol       Date:  2015-07-24       Impact factor: 4.849

10.  The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Authors:  Daniel M Hartung; Dennis N Bourdette; Sharia M Ahmed; Ruth H Whitham
Journal:  Neurology       Date:  2015-04-24       Impact factor: 9.910

  10 in total
  1 in total

1.  The financial contribution of the multiple sclerosis specialist.

Authors:  James N Goldenberg
Journal:  Neurol Clin Pract       Date:  2017-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.